The effectiveness of using misoprostol with and without letrozole for successful medical abortion: A randomized placebo-controlled clinical trial

Elham Naghshineh, Zahra Allame, Faezah Farhat, Elham Naghshineh, Zahra Allame, Faezah Farhat

Abstract

Background: In developing countries it is important to the exploration of available and safe regimens for medical abortion. The present study was designed to assess the effect of letrozole compared to placebo pretreatment followed by sublingual misoprostol for therapeutic abortion in eligible women with gestational age less than 17 weeks.

Materials and methods: In this randomized control trail, 130 women eligible for legal abortions were randomly divided into two groups of case and controls. Cases received daily oral dose of 10 mg letrozole 10 mg letrozole for three days followed by sublingual misoprostol. Controls received daily oral dose of placebo followed by sublingual misoprostol. The dose of misoprostol was administrated according to ACOG guidelines based on patients' gestational age. The rate of complete abortion, induction-of-abortion time, and side-effects were assessed as main outcomes.

Results: Complete abortion was observed in 46 (76.7%) letrozole group and 26 (42.6%) controls (P < 0.0001). Also, in 14 subjects of letrozole group and 35 subjects in placebo group, the placenta was not delivered during follow-up and curettage was performed. The mean interval induction-to-abortion was 5.1 h in letrozole group and 8.9 h in control (P < 0.0001). The cumulative rates of the induction-of-abortion time were a significant difference between the two groups (P < 0.0001). The incidence and severity of side-effects was comparable for the two groups (P = 0.9).

Conclusion: Letrozole could be a quite beneficial adjuvant to misoprostol for induction of complete abortion in those who are candidates for legal medical abortion.

Keywords: Letrozole; medical abortion; misoprostol.

Figures

Figure 1
Figure 1
Patients study flow diagram
Figure 2
Figure 2
Kaplan-Meier estimates of the abortion in both letrozole and control groups

References

    1. Sedgh G, Bankole A, Oye-Adeniran B, Adewole IF, Singh S, Hussain R. Unwanted pregnancy and associated factors among Nigerian women. Int Fam Plan Perspect. 2006;32:175–84.
    1. Sedgh G, Henshaw S, Singh S, Ahman E, Shah IH. Induced abortion: Estimated rates and trends worldwide. Lancet. 2007;370:1338–45.
    1. Shah I, Ahman E. Unsafe abortion in 2008: Global and regional levels and trends. Reprod Health Matters. 2010;18:90–101.
    1. Shaikh Z, Abbassi RM, Rizwan N, Abbasi S. Morbidity and mortality due to unsafe abortion in Pakistan. Int J Gynaecol Obstet. 2010;110:47–9.
    1. Hosseini SH. The development of Australian abortion laws in a worldwide trend, free and legal practices of abortion and a glance at abortion laws in Iran. J Reprod Infertil. 2007;4:398–409.
    1. Behjati A, Akhoundi MM, Sadeghi MR, Sadriardekani H. The necessity of a comprehensive study on abortion in Iran. J Reprod Infertil. 2005;4:299–320.
    1. Rustamnezhad M, Asadzadeh F, Mustafazadeh F, Karami R, Kazemzadeh R. Study on abortion cases referred to the Forensic Medicine Center of Ardebil city. Health Care J. 2011;11:38–42.
    1. ACOG. ACOG practice bulletin. Clinical management guidelines of obstetrician-gynecologists. Number 67, October 2005. Medical management of abortion. Obstet Gynecol. 2005;106:871–82.
    1. Winikoff B, Sivin I, Coyaji KJ, Cabezas E, Xiao B, Gu S, et al. Safety, efficacy, and acceptability of medical abortion in China, Cuba, and India: A comparative trial of mifepristone-misoprostol versus surgical abortion. Am J Obstet Gynecol. 1997;176:431–7.
    1. Schaub B, Fuhrer P, Sainte-Rose D. Randomized study of sulprostone versus misoprostol in the cervical preparation before elective abortion in nulliparous women. J Gynecol Obstet Biol Reprod (Paris) 1995;24:505–10.
    1. Ho PC, Blumenthal PD, Gemzell-Danielsson K, Gómez Ponce de León R, Mittal S, Tang OS. Misoprostol for the termination of pregnancy with a live fetus at 13 to 26 weeks. Int J Gynaecol Obstet. 2007;99(Suppl 2):S178–81.
    1. Tanha FD, Golgachi T, Niroomand N, Ghajarzadeh M, Nasr R. Sublingual versus vaginal misoprostol for second trimester termination: A randomized clinical trial. Arch Gynecol Obstet. 2013;287:65–9.
    1. von Hertzen H, Piaggio G, Wojdyla D, Nguyen TM, Marions L, Okoev G, et al. Comparison of vaginal and sublingual misoprostol for second trimester abortion: Randomized controlled equivalence trial. Hum Reprod. 2009;24:106–12.
    1. Kapp N, Borgatta L, Stubblefield P, Vragovic O, Moreno N. Mifepristone in second-trimester medical abortion: A randomized controlled trial. Obstet Gynecol. 2007;110:1304–10.
    1. Lee VC, Tang OS, Ng EH, Yeung WS, Ho PC. A prospective double-blinded, randomized, placebo-controlled trial on the use of letrozole pretreatment with misoprostol for second-trimester medical abortion. Contraception. 2011;84:628–33.
    1. Lee VC, Ng EH, Yeung WS, Ho PC. Misoprostol with or without letrozole pretreatment for termination of pregnancy: A randomized controlled trial. Obstet Gynecol. 2011;117(2 Pt 1):317–23.
    1. Mitwally MF, Casper RF. Single-dose administration of an aromatase inhibitor for ovarian stimulation. Fertil Steril. 2005;83:229–31.
    1. Holzer H, Casper R, Tulandi T. A new era in ovulation induction. Fertil Steril. 2006;85:277–84.
    1. Ashok PW, Penney GC, Flett GM, Templeton A. An effective regimen for early medical abortion: A report of 2000 consecutive cases. Hum Reprod. 1998;13:2962–5.
    1. Schaff EA, Eisinger SH, Stadalius LS, Franks P, Gore BZ, Poppema S. Low-dose mifepristone 200 mg and vaginal misoprostol for abortion. Contraception. 1999;59:1–6.
    1. Behnamfar F, Mahdian M, Rahimi F, Samimi M. Misoprostol abortion: Ultrasonography versus Beta-hCG testing for verification of effectiveness. Pak J Med Sci. 2013;29:1367–70.
    1. Yilmaz B, Kelekci S, Ertas IE, Ozel M, Sut N, Mollamahmutoglu L, et al. Randomized comparison of second trimester pregnancy termination utilizing saline moistened or dry misoprostol. Arch Gynecol Obstet. 2007;276:511–6.
    1. Wong KS, Ngai CS, Yeo EL, Tang LC, Ho PC. A comparison of two regimens of intravaginal misoprostol for termination of second trimester pregnancy: A randomized comparative trial. Hum Reprod. 2000;15:709–12.
    1. Wong KS, Ngai CS, Wong AY, Tang LC, Ho PC. Vaginal misoprostol compared with vaginal gemeprost in termination of second trimester pregnancy. A randomized trial. Contraception. 1998;58:207–10.
    1. Tang OS, Chan CC, Kan AS, Ho PC. A prospective randomized comparison of sublingual and oral misoprostol when combined with mifepristone for medical abortion at 12-20 weeks gestation. Hum Reprod. 2005;20:3062–6.
    1. Bhattacharjee N, Saha SP, Ganguly RP, Patra KK, Jha T, Barui G, et al. A randomized comparative study on vaginal administration of acetic acid-moistened versus dry misoprostol for mid-trimester pregnancy termination. Arch Gynecol Obstet. 2012;285:311–6.
    1. Yeung TW, Lee VC, Ng EH, Ho PC. A pilot study on the use of a 7-day course of letrozole followed by misoprostol for the termination of early pregnancy up to 63 days. Contraception. 2012;86:763–9.
    1. Chai J, Ho PC. A pilot study on the combined use of letrozole, mifepristone and misoprostol in termination of first trimester pregnancy up to 9 weeks’ gestation. Eur J Obstet Gynecol Reprod Biol. 2013;171:291–4.
    1. Milani F, Sharami SH, Arjmandi S. Comparison of sublingual and vaginal misoprostol for second-trimester pregnancy terminations. J Family Reprod Health. 2014;8:41–4.
    1. von Hertzen H, Huong NT, Piaggio G, Bayalag M, Cabezas E, Fang AH, et al. Misoprostol dose and route after mifepristone for early medical abortion: A randomised controlled noninferiority trial. BJOG. 2010;117:1186–96.
    1. Saxena P, Salhan S, Sarda N. Role of sublingual misoprostol for cervical ripening prior to vacuum aspiration in first trimester interruption of pregnancy. Contraception. 2003;67:213–7.
    1. Tang OS, Lau WN, Chan CC, Ho PC. A prospective randomised comparison of sublingual and vaginal misoprostol in second trimester termination of pregnancy. BJOG. 2004;111:1001–5.
    1. Lee VC, Tang OS, Ng EH, Yeung WS, Ho PC. A pilot study on the use of letrozole with either misoprostol or mifepristone for termination of pregnancy up to 63 days. Contraception. 2011;83:62–7.

Source: PubMed

Sponsoren und Mitarbeiter

Krankheiten

Drogeninterventionen

3
Abonnieren